Differential potential for envelope glycoprotein-mediated steric shielding of host cell surface proteins among filoviruses

Virology

Volumn 446, Issue 1-2, 2013, Pages 152-161

  Noyori, Osamu ^a   Matsuno, Keita ^a,c   Kajihara, Masahiro ^a   Nakayama, Eri ^a,d   Igarashi, Manabu ^a   Kuroda, Makoto ^a   Isoda, Norikazu ^a   Yoshida, Reiko ^a   Takada, Ayato ^a,b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b UNIVERSITY OF ZAMBIA   (Zambia)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Ebola virus; Glycoprotein; Integrin; Marburg virus; MHC; Pathogenicity; Steric shielding

Indexed keywords

BETA ACTIN; BETA1 INTEGRIN; CELL SURFACE PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUCIN; VIRUS ENVELOPE PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FILOVIRUS; HOST CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN STABILITY; STRAIN DIFFERENCE; VIRUS CELL INTERACTION; VIRUS STRAIN; VIRUS VIRULENCE;

EBOLA VIRUS; GLYCOPROTEIN; INTEGRIN; MARBURG VIRUS; MHC; PATHOGENICITY; STERIC SHIELDING;

CELL LINE; DNA MUTATIONAL ANALYSIS; FILOVIRIDAE; HOST-PATHOGEN INTERACTIONS; HUMANS; MEMBRANE PROTEINS; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; VIRAL ENVELOPE PROTEINS; VIRULENCE;

EID: 84884528527     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.07.029     Document Type: Article

References (45)

1. Alazard-Dany N., Volchkova V., Reynard O., Carbonnelle C., Dolnik O., Ottmann M., Khromykh A., Volchkov V.E. Ebola virus glycoprotein GP is not cytotoxic when expressed constitutively at a moderate level. J. Gen. Virol. 2006, 87:1247-1257.
2. Andersson M., Pääbo S., Nilsson T., Peterson P.A. Impaired intracellular transport of class I MHC antigens as a possible means for adenoviruses to evade immune surveillance. Cell 1985, 43:215-222.
3. Bausch D.G., Nichol S.T., Muyembe-Tamfum J.J., Borchert M., Rollin P.E., Sleurs H., Campbell P., Tshioko F.K., Roth C., Colebunders R., Pirard P., Mardel S., Olinda L.A., Zeller H., Tshomba A., Kulidri A., Libande M.L., Mulangu S., Formenty P., Grein T., Leirs H., Braack L., Ksiazek T., Zaki S., Bowen M.D., Smit S.B., Leman P.A., Burt F.J., Kemp A., Swanepoel R. International Scientific and Technical Committee for Marburg Hemorrhagic Fever Control in the Democratic Republic of the Congo. Marburg hemorrhagic fever associated with multiple genetic lineages of virus. N. Engl. J. Med. 2006, 355:909-919.
4. Bausch D.G., Sprecher A.G., Jeffs B., Boumandouki P. Treatment of Marburg and Ebola hemorrhagic fevers: a strategy for testing new drugs and vaccines under outbreak conditions. Antiviral Res. 2008, 78:150-161.
5. Bavari S., Bosio C.M., Wiegand E., Ruthel G., Will A.B., Geisbert T.W., Hevey M., Schmaljohn C., Schmaljohn A., Aman M.J. Lipidraftmicrodomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J. Exp. Med. 2002, 195:593-602.
6. Bene L., Bodnár A., Damjanovich S., Vámosi G., Bacsó Z., Aradi J., Berta A., Damjanovich J. Membrane topography of HLA I, HLA II, and ICAM-1 is affected by IFN-gamma in lipid rafts of uveal melanomas. Biochem. Biophys. Res. Commun. 2004, 322:678-683.
7. Blagoveshchenskaya A.D., Thomas L., Feliciangeli S.F., Hung C.H., Thomas G. HIV-1 Nefdownregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway. Cell 2002, 111:853-866.
8. Blumenthal A., Giebel J., Ummanni R., Schlüter R., Endlich K., Endlich N. Morphology and migration of podocytes are affected by CD151 levels. Am. J. Physiol. Renal. Physiol. 2012, 302:F1265-1277.
9. Chan S.Y., Ma M.C., Goldsmith M.A. Differential induction of cellular detachment by envelope glycoproteins of Marburg and Ebola (Zaire) viruses. J. Gen. Virol. 2000, 81:2155-2159.
10. Daddario-DiCaprio K.M., Geisbert T.W., Geisbert J.B., Ströher U., Hensley L.E., Grolla A., Fritz E.A., Feldmann F., Feldmann H., Jones S.M. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J. Virol. 2006, 80:9659-9666.
11. Davis K.J., Anderson A.O., Geisbert T.W., Steele K.E., Geisbert J.B., Vogel P., Connolly B.M., Huggins J.W., Jahrling P.B., Jaax N.K. Pathology of experimental Ebola virus infection in African green monkeys. Involvement of fibroblastic reticular cells. Arch. Pathol. Lab. Med. 1997, 121:805-819.
12. Dube D., Brecher M.B., Delos S.E., Rose S.C., Park E.W., Schornberg K.L., Kuhn J.H., White J.M. The primed Ebolavirus glycoprotein (19-kilodalton GP1,2): sequence and residues critical for host cell binding. J. Virol. 2009, 83:2883-2891.
13. Feldmann H., Geisbert T.W. Ebolahaemorrhagic fever. Lancet 2011, 377:849-862.
14. Francica J.R., Matukonis M.K., Bates P. Requirements for cell rounding and surface protein down-regulation by Ebolavirus glycoprotein. Virology 2009, 383:237-247.
15. Francica J.R., Varela-Rohena A., Medvec A., Plesa G., Riley J.L., Bates P. Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. PloS Pathog. 2010, 6:1-12.
16. Geisbert T.W., Daddario-DiCaprio K.M., Geisbert J.B., Young H.A., Formenty P., Fritz E.A., Larsen T., Hensley L.E. Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2. J. Infect. Dis. 2007, 196(Suppl 2):S372-S381.
17. Geisbert T.W., Hensley L.E. Ebola virus: new insights into disease aetiopathology and possible therapeutic interventions. Expert Rev. Mol. Med. 2004, 6:1-24.
18. Groseth A., Marzi A., Hoenen T., Herwig A., Gardner D., Becker S., Ebihara H., Feldmann H. The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PloS Pathog. 2012, 8(8):e1002847.
19. Harrison J.S., Koellhoffer J.F., Chandran K., Lai J.R. Marburg virus glycoprotein GP2: pH-dependent stability of the ectodomain α-helical bundle. Biochemistry 2012, 51:2515-2525.
20. Ishido S., Wang C., Lee B.S., Cohen G.B., Jung J.U. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J. Virol. 2000, 74:5300-5309.
21. Jeffers S.A., Sanders D.A., Sanchez A. Covalent modifications of the ebola virus glycoprotein. J. Virol. 2002, 76:12463-12472.
22. Kajihara M., Marzi A., Nakayama E., Noda T., Kuroda M., Manzoor R., Matsuno K., Feldmann H., Yoshida R., Kawaoka Y., Takada A. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J. Virol. 2012, 86:13467-13474.
23. Kuhn J.H., Radoshitzky S.R., Guth A.C., Warfield K.L., Li W., Vincent M.J., Towner J.S., Nichol S.T., Bavari S., Choe H., Aman M.J., Farzan M. Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. J. Biol. Chem. 2006, 281:15951-15958.
24. Lee J.E., Fusco M.L., Hessell A.J., Oswald W.B., Burton D.R., Saphire E.O. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 2008, 454:177-182.
25. Mahanty S., Bray M. Pathogenesis of filoviral haemorrhagic fevers. Lancet Infect. Dis. 2004, 4:487-498.
26. Matsuno K., Kishida N., Usami K., Igarashi M., Yoshida R., Nakayama E., Shimojima M., Feldmann H., Irimura T., Kawaoka Y., Takada A. Differentpotential of C-type lectin-mediated entry between Marburg virus strains. J. Virol. 2010, 84:5140-5147.
27. Nakayama E., Tomabechi D., Matsuno K., Kishida N., Yoshida R., Feldmann H., Takada A. Antibody-dependent enhancement of Marburg virus infection. J. Infect. Dis. 2011, 204(Suppl 3):S978-S985.
28. Nakayama E., Yokoyama A., Miyamoto H., Igarashi M., Kishida N., Matsuno K., Marzi A., Feldmann H., Ito K., Saijo M., Takada A. Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies. Clin.Vaccine Immunol. 2010, 17:1723-1728.
29. Ray R.B., Basu A., Steele R., Beyene A., McHowat J., Meyer K., Ghosh A.K., Ray R. Ebola virus glycoprotein-mediated anoikis of primary human cardiac microvascular endothelial cells. Virology 2004, 321:181-188.
30. Reynard O., Borowiak M., Volchkova V.A., Delpeut S., Mateo M., Volchkov V.E. Ebolavirus glycoprotein GPmasks both its own epitopes and the presence of cellular surface proteins. J. Virol. 2009, 83:9596-9601.
31. Sanchez A., Geisbert W.T., Feldmann H. Filoviridae: Marburg and Ebola viruses. Field's Virology 2007, 1409-1448.
32. Schnittler H.J., Feldmann H. Molecular pathogenesis of filovirus infections: role of macrophages and endothelial cells. Curr. Top. Microbiol. Immunol. 1999, 235:175-204.
33. Simmons G., Wool-Lewis R.J., Baribaud F., Netter R.C., Bates P. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. J. Virol. 2002, 76:2518-2528.
34. Smith D.H., Johnson B.K., Isaacson M., Swanapoel R., Johnson K.M., Killey M., Bagshawe A., Siongok T., Keruga W.K. Marburg-virus disease in Kenya. Lancet 1982, 1:816-820.
35. Sullivan N.J., Peterson M., Yang Z.Y., Kong W.P., Duckers H., Nabel E., Nabel G.J. Ebola virus glycoprotein toxicity is mediated by a dynamin-dependent protein-trafficking pathway. J. Virol. 2005, 79:547-553.
36. Takada A., Ebihara H., Feldmann H., Geisbert T.W., Kawaoka Y. Epitopesrequired for antibody-dependent enhancement of Ebola virus infection. J. Infect. Dis. 2007, 196(Suppl 2):S347-356.
37. Takada A., Fujioka K., Tsuiji M., Morikawa A., Higashi N., Ebihara H., Kobasa D., Feldmann H., Irimura T., Kawaoka Y. Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. J. Virol. 2004, 78:2943-2947.
38. Takada A., Watanabe S., Ito H., Okazaki K., Kida H., Kawaoka Y. Downregulation of beta1 integrins by Ebola virus glycoprotein: implication for virus entry. Virology 2000, 278:20-26.
39. Takada A., Watanabe S., Okazaki K., Kida H., Kawaoka Y. Infectivity-enhancing antibodies to Ebola virus glycoprotein. J. Virol. 2001, 75:2324-2330.
40. Volchkov V.E., Feldmann H., Volchkova V.A., Klenk H.D. Processing of the Ebola virus glycoprotein by the proproteinconvertasefurin. Proc. Natl. Acad. Sci. USA 1998, 95:5762-5767.
41. Volchkov, V.E., Volchkova, V.A., Muhlberger, E., Kolesnikova, L.V., Weik, M., Dolnik, O., Klenk H.D., 2001. Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. Science 291, 1965-1969.
42. Volchkov V.E., Volchkova V.A., Ströher U., Becker S., Dolnik O., Cieplik M., Garten W., Klenk H.D., Feldmann H. Proteolytic processing of Marburg virus glycoprotein. Virology 2000, 268:1-6.
43. Wadehra M., Su H., Gordon L.K., Goodglick L., Braun J. The tetraspan protein EMP2 increases surface expression of class I major histocompatibility complex proteins and susceptibility to CTL-mediated cell death. Clin. Immunol. 2003, 107:129-136.
44. Weissenhorn W., Carfí A., Lee K.H., Skehel J.J., Wiley D.C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. Mol. Cell 1998, 2:605-616.
45. Yang Z.Y., Duckers H.J., Sullivan N.J., Sanchez A., Nabel E.G., Nabel G.J. Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat. Med. 2000, 6:886-889.